MK TEST ESMO Asia Congress 2022
Singapore 02 December 2023 - 06 December 2023
Relugolix effective, well tolerated in Asian men with advanced prostate cancer
In the subgroup analysis of the HERO trial, the first-in-class oral, highly selective, GnRH* antagonist relugolix was effective and well tolerated in Asian men with advanced prostate cancer.
Relugolix effective, well tolerated in Asian men with advanced prostate cancer
23 Dec 2022
Maintenance olaparib confers survival benefit for HRD+ ovarian cancer patients
In the final overall survival (OS) analysis of the phase III PAOLA-1*/ENGOT-ov25 trial, the addition of olaparib to bevacizumab provided a survival benefit for women with newly diagnosed advanced ovarian cancer with HRD**-positive (HRD+) tumours.
Maintenance olaparib confers survival benefit for HRD+ ovarian cancer patients
19 Dec 2022
Prostate cancer genomic study shows disparity between Chinese and Caucasians with castration-sensitive disease
A large genomic study involving 1,016 Chinese patients with prostate cancer has revealed important differences in castration-sensitive disease between Chinese and Caucasian patients, but the mutation profile of metastatic castration-resistant prostate cancer (mCRPC) is similar between the populations.
Prostate cancer genomic study shows disparity between Chinese and Caucasians with castration-sensitive disease
13 Dec 2022
Asians with MET exon 14 skipping NSCLC achieve durable response with tepotinib
The MET inhibitor tepotinib demonstrates clinically meaningful antitumour activity, with durable efficacy and manageable safety profile in Asian nonsmall cell lung cancer (NSCLC) patients with MET mutations associated with exon 14 skipping, as shown in the subset analysis of the single-arm, phase II VISION study.
Asians with MET exon 14 skipping NSCLC achieve durable response with tepotinib
12 Dec 2022
Amivantamab/lazertinib combo shows promise in EGFR-mutated NSCLC
Among nonsmall cell lung cancer (NSCLC) patients with mutations spanning exons 18 to 21, combination treatment with amivantamab and lazertinib induces high rates of response, reports a study presented at the recent 2022 European Society for Medical Oncology Asia Congress (ESMO Asia 2022).